Insmed Incorporated (INSM)
USD 67.96
(4.86%)
USD 67.96
(4.86%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -654.73 Million USD | -47.08% |
| 2022 | -429.43 Million USD | -22.72% |
| 2021 | -375.09 Million USD | -43.7% |
| 2020 | -250.37 Million USD | -12.58% |
| 2019 | -215.67 Million USD | 24.45% |
| 2018 | -293.77 Million USD | -61.96% |
| 2017 | -184.09 Million USD | -8.85% |
| 2016 | -170.23 Million USD | -47.44% |
| 2015 | -115.28 Million USD | -34.74% |
| 2014 | -86.09 Million USD | -60.43% |
| 2013 | -54.2 Million USD | -29.83% |
| 2012 | -40.05 Million USD | -18.34% |
| 2011 | -59.31 Million USD | -340.23% |
| 2010 | -6.19 Million USD | -0.89% |
| 2009 | 120.31 Million USD | 38.09% |
| 2008 | -13.36 Million USD | 35.77% |
| 2007 | -18.87 Million USD | 54.37% |
| 2006 | -49.06 Million USD | -201.99% |
| 2005 | -13.78 Million USD | 46.93% |
| 2004 | -27.16 Million USD | -164.11% |
| 2003 | -10.49 Million USD | 36.09% |
| 2002 | -34.14 Million USD | 58.01% |
| 2001 | -38.64 Million USD | -292.05% |
| 2000 | -30.31 Million USD | 350.16% |
| 1999 | -8.04 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -182.5 Million USD | -107.98% |
| 2024 Q3 | -213.42 Million USD | 28.73% |
| 2024 Q1 | -154.55 Million USD | 17.91% |
| 2023 Q4 | -158.62 Million USD | -15.95% |
| 2023 Q1 | -147 Million USD | 1.39% |
| 2023 Q2 | -221.59 Million USD | -50.74% |
| 2023 Q3 | -136.8 Million USD | 38.26% |
| 2023 FY | - USD | -47.08% |
| 2022 Q2 | -91.22 Million USD | -2.09% |
| 2022 Q4 | -149.08 Million USD | -17.3% |
| 2022 Q3 | -127.09 Million USD | -39.33% |
| 2022 FY | - USD | -22.72% |
| 2022 Q1 | -89.35 Million USD | 11.06% |
| 2021 Q4 | -100.46 Million USD | 0.66% |
| 2021 Q2 | -85.53 Million USD | -6.15% |
| 2021 Q1 | -80.57 Million USD | 13.23% |
| 2021 FY | - USD | -43.7% |
| 2021 Q3 | -101.13 Million USD | -18.24% |
| 2020 Q4 | -92.86 Million USD | -75.1% |
| 2020 Q1 | -57.15 Million USD | -23.95% |
| 2020 FY | - USD | -12.58% |
| 2020 Q2 | -50.99 Million USD | 10.78% |
| 2020 Q3 | -53.03 Million USD | -4.0% |
| 2019 FY | - USD | 24.45% |
| 2019 Q3 | -54.66 Million USD | 9.1% |
| 2019 Q4 | -46.11 Million USD | 15.66% |
| 2019 Q1 | -67.66 Million USD | 21.71% |
| 2019 Q2 | -60.14 Million USD | 11.11% |
| 2018 Q1 | -62.24 Million USD | 4.62% |
| 2018 Q4 | -86.42 Million USD | -3.84% |
| 2018 FY | - USD | -61.96% |
| 2018 Q2 | -71.7 Million USD | -15.2% |
| 2018 Q3 | -83.22 Million USD | -16.06% |
| 2017 FY | - USD | -8.85% |
| 2017 Q4 | -65.25 Million USD | -50.83% |
| 2017 Q1 | -35.34 Million USD | 47.26% |
| 2017 Q2 | -42.57 Million USD | -20.45% |
| 2017 Q3 | -43.26 Million USD | -1.62% |
| 2016 FY | - USD | -47.44% |
| 2016 Q4 | -67.02 Million USD | -83.98% |
| 2016 Q3 | -36.43 Million USD | -2.52% |
| 2016 Q2 | -35.53 Million USD | -7.51% |
| 2016 Q1 | -33.05 Million USD | -1.43% |
| 2015 Q3 | -29.84 Million USD | -8.5% |
| 2015 Q2 | -27.51 Million USD | -4.85% |
| 2015 Q1 | -26.23 Million USD | -13.7% |
| 2015 FY | - USD | -34.74% |
| 2015 Q4 | -32.58 Million USD | -9.17% |
| 2014 FY | - USD | -60.43% |
| 2014 Q3 | -23.05 Million USD | -1.82% |
| 2014 Q2 | -22.64 Million USD | -26.27% |
| 2014 Q1 | -17.93 Million USD | -16.27% |
| 2014 Q4 | -23.07 Million USD | -0.1% |
| 2013 Q2 | -8.11 Million USD | 42.71% |
| 2013 Q4 | -15.42 Million USD | 7.49% |
| 2013 FY | - USD | -29.83% |
| 2013 Q1 | -14.16 Million USD | 9.74% |
| 2013 Q3 | -16.67 Million USD | -105.49% |
| 2012 Q2 | -9.84 Million USD | -38.12% |
| 2012 Q3 | -9.21 Million USD | 6.4% |
| 2012 Q4 | -15.68 Million USD | -70.26% |
| 2012 FY | - USD | -18.34% |
| 2012 Q1 | -7.12 Million USD | 18.63% |
| 2011 Q1 | -7.34 Million USD | -16.49% |
| 2011 FY | - USD | -340.23% |
| 2011 Q2 | -10.39 Million USD | -41.61% |
| 2011 Q3 | -8.97 Million USD | 13.7% |
| 2011 Q4 | -8.76 Million USD | 2.34% |
| 2010 Q1 | -226 Thousand USD | -158.1% |
| 2010 Q2 | -913 Thousand USD | -303.98% |
| 2010 Q3 | -598 Thousand USD | 34.5% |
| 2010 Q4 | -6.3 Million USD | -953.68% |
| 2010 FY | - USD | -0.89% |
| 2009 Q1 | -6.71 Million USD | -91.53% |
| 2009 Q3 | -764 Thousand USD | 4.26% |
| 2009 Q4 | 389 Thousand USD | 150.92% |
| 2009 FY | - USD | 38.09% |
| 2009 Q2 | -798 Thousand USD | 88.12% |
| 2008 Q2 | -4.11 Million USD | 0.07% |
| 2008 Q4 | -3.5 Million USD | -121.88% |
| 2008 Q1 | -4.11 Million USD | -28.68% |
| 2008 FY | - USD | 35.77% |
| 2008 Q3 | -1.58 Million USD | 61.54% |
| 2007 Q4 | -3.19 Million USD | 20.71% |
| 2007 Q3 | -4.03 Million USD | -62.38% |
| 2007 Q2 | -2.48 Million USD | 75.94% |
| 2007 Q1 | -10.32 Million USD | 50.69% |
| 2007 FY | - USD | 54.37% |
| 2006 Q3 | -12.63 Million USD | -36.74% |
| 2006 Q2 | -9.24 Million USD | -12.78% |
| 2006 Q4 | -20.93 Million USD | -65.65% |
| 2006 Q1 | -8.19 Million USD | -481.96% |
| 2006 FY | - USD | -201.99% |
| 2005 Q1 | -5.29 Million USD | 9.91% |
| 2005 FY | - USD | 46.93% |
| 2005 Q2 | -5.6 Million USD | -5.8% |
| 2005 Q3 | -2.22 Million USD | 60.24% |
| 2005 Q4 | -1.4 Million USD | 36.8% |
| 2004 Q2 | -9.05 Million USD | -87.72% |
| 2004 Q1 | -4.82 Million USD | -93.69% |
| 2004 FY | - USD | -164.11% |
| 2004 Q4 | -5.88 Million USD | 23.04% |
| 2004 Q3 | -7.64 Million USD | 15.58% |
| 2003 Q2 | -3.28 Million USD | -44.65% |
| 2003 FY | - USD | 36.09% |
| 2003 Q1 | -2.27 Million USD | 29.41% |
| 2003 Q4 | -2.48 Million USD | -1.8% |
| 2003 Q3 | -2.44 Million USD | 25.57% |
| 2002 Q3 | -2.18 Million USD | 104.83% |
| 2002 Q4 | -18.6 Million USD | -1029.77% |
| 2002 Q2 | -7.16 Million USD | -15.73% |
| 2002 Q1 | -6.19 Million USD | 36.66% |
| 2002 FY | - USD | 58.01% |
| 2001 Q4 | -9.77 Million USD | -13.5% |
| 2001 FY | - USD | -292.05% |
| 2001 Q2 | -9.26 Million USD | 15.66% |
| 2001 Q1 | -10.98 Million USD | -126.28% |
| 2001 Q3 | -8.61 Million USD | 7.08% |
| 2000 Q1 | -11.39 Million USD | 0.0% |
| 2000 FY | - USD | 350.16% |
| 2000 Q2 | -55.5 Million USD | -386.99% |
| 2000 Q4 | 41.82 Million USD | 900.23% |
| 2000 Q3 | -5.22 Million USD | 90.58% |
| 1999 Q2 | -1.65 Million USD | -6.15% |
| 1999 Q1 | -1.56 Million USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Caribou Biosciences, Inc. | -112.53 Million USD | -481.814% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | -3188.098% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | -2018.622% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | -1297.164% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | -311.659% |
| C4 Therapeutics, Inc. | -122.1 Million USD | -436.219% |
| Agenus Inc. | -145.92 Million USD | -348.685% |
| Fortress Biotech, Inc. | -133.64 Million USD | -389.916% |
| GlycoMimetics, Inc. | -39.12 Million USD | -1573.583% |
| Novavax, Inc. | -487.39 Million USD | -34.336% |
| Keros Therapeutics, Inc. | -152.17 Million USD | -330.248% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -224896.22% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | -603.884% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -203868.536% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | -9433.183% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | -153.537% |
| AlloVir, Inc. | -190.14 Million USD | -244.335% |
| Aptorum Group Limited | -9.59 Million USD | -6720.911% |
| Ardelyx, Inc. | -55.35 Million USD | -1082.821% |
| Bicycle Therapeutics plc | -183.4 Million USD | -257.001% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | -295.802% |
| Chimerix, Inc. | -92.97 Million USD | -604.217% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -1373.419% |
| CRISPR Therapeutics AG | -202.7 Million USD | -223.007% |
| Clearside Biomedical, Inc. | -23.05 Million USD | -2739.531% |
| Precision BioSciences, Inc. | -32.04 Million USD | -1943.377% |
| Dyadic International, Inc. | -8.22 Million USD | -7855.769% |
| Elevation Oncology, Inc. | -41.46 Million USD | -1478.94% |
| Fortress Biotech, Inc. | -133.64 Million USD | -389.916% |
| GT Biopharma, Inc. | 5.97 Million USD | 11050.644% |
| Alkermes plc | 495.04 Million USD | 232.257% |
| Immix Biopharma, Inc. | -16.13 Million USD | -3957.718% |
| Innoviva, Inc. | 248.96 Million USD | 362.99% |
| IO Biotech, Inc. | -91.22 Million USD | -617.695% |
| Jaguar Health, Inc. | -33.13 Million USD | -1876.213% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 743.624% |
| ContextLogic Inc. | -324 Million USD | -102.08% |
| AbCellera Biologics Inc. | -192.15 Million USD | -240.73% |
| Lantern Pharma Inc. | -15.78 Million USD | -4047.412% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -7698.225% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | -272.705% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | -72.314% |
| MEI Pharma, Inc. | 26.38 Million USD | 2581.952% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | -775.146% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -2615.419% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | -421.717% |
| NextCure, Inc. | -59.03 Million USD | -1008.994% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | -746.539% |
| ChromaDex Corporation | -3.89 Million USD | -16714.047% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | -402.02% |
| Incyte Corporation | 919.42 Million USD | 171.212% |
| Opthea Limited | -200.01 Million USD | -227.339% |
| MiMedx Group, Inc. | 40.51 Million USD | 1715.961% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | -1041.139% |
| Aadi Bioscience, Inc. | -65.36 Million USD | -901.666% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -23695.02% |
| Vaxcyte, Inc. | -464.88 Million USD | -40.839% |
| PDS Biotechnology Corporation | -40.08 Million USD | -1533.378% |
| Pharming Group N.V. | 9.87 Million USD | 6728.926% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | -2776.456% |
| Onconetix, Inc. | -36.7 Million USD | -1683.703% |
| Acelyrin, Inc. | -381.52 Million USD | -71.611% |
| PureTech Health plc | -11.62 Million USD | -5531.195% |
| Pyxis Oncology, Inc. | -78.49 Million USD | -734.137% |
| Avidity Biosciences, Inc. | -233.49 Million USD | -180.406% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -3542.812% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -2615.419% |
| ESSA Pharma Inc. | -26.45 Million USD | -2374.887% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -3755.715% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -6468.409% |
| Seer, Inc. | -97.88 Million USD | -568.886% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -648.898% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 123869.187% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | -2160.605% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -5081348.115% |
| Summit Therapeutics Inc. | 1 Million USD | 65508.492% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | -1861.118% |
| Senti Biosciences, Inc. | -61.33 Million USD | -967.463% |
| ImmuCell Corporation | -2.5 Million USD | -26046.92% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | -316.514% |
| Janux Therapeutics, Inc. | -71.02 Million USD | -821.856% |
| Precigen, Inc. | -89.22 Million USD | -633.798% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -1053.644% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 29394.81% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | -483.006% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -2658.538% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -10604.391% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | -21.264% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | -952.686% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | -1917.499% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -2137.812% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -3147.874% |
| Wave Life Sciences Ltd. | -58.79 Million USD | -1013.691% |
| Fate Therapeutics, Inc. | -172.22 Million USD | -280.156% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -9411.026% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | -216.769% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 854.203% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | -1178.313% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -6522.285% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | -176.703% |
| Aptose Biosciences Inc. | -52.26 Million USD | -1152.657% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | -507.684% |
| Soligenix, Inc. | -7.85 Million USD | -8237.597% |
| Century Therapeutics, Inc. | -121.2 Million USD | -440.178% |
| Kura Oncology, Inc. | -164.95 Million USD | -296.92% |
| TScan Therapeutics, Inc. | -80.09 Million USD | -717.422% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -6391.563% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -68262.988% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -15094.686% |
| Autolus Therapeutics plc | -156.77 Million USD | -317.643% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | -673.402% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | -848.883% |
| Eterna Therapeutics Inc. | -19.93 Million USD | -3184.534% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | -245.923% |
| GRI Bio, Inc. | -10.89 Million USD | -5907.882% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -14399.121% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | -434.455% |
| IGM Biosciences, Inc. | -253.35 Million USD | -158.424% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -530.818% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -1616.978% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -4170.713% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -4058.857% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | -1051.797% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | -511.317% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | -146.145% |
| Coherus BioSciences, Inc. | -193.93 Million USD | -237.6% |
| Verastem, Inc. | -83.16 Million USD | -687.268% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -1194.667% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | -313.795% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | -473.884% |
| Histogen Inc. | -10.5 Million USD | -6133.828% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -4485.101% |
| Surrozen, Inc. | -41.13 Million USD | -1491.838% |
| Organovo Holdings, Inc. | -14.8 Million USD | -4322.119% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 20416033.895% |
| Ovid Therapeutics Inc. | -58.71 Million USD | -1015.148% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -1176.444% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | -2939.784% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -7752.466% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | -294.264% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | -1229.191% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | -2609.34% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -4248.969% |
| Apollomics, Inc. | -171.74 Million USD | -281.223% |
| Amarin Corporation plc | -50.9 Million USD | -1186.285% |
| Mesoblast Limited | -61.33 Million USD | -967.55% |
| Turnstone Biologics Corp. | -56.23 Million USD | -1064.312% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | -357.217% |
| Synaptogenix, Inc. | -8.3 Million USD | -7781.293% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -4168.459% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | -938.494% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -13564.691% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 152705.94% |
| Exelixis, Inc. | 196.6 Million USD | 433.028% |
| Better Therapeutics, Inc. | -38.26 Million USD | -1611.199% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | -363.011% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | -32.214% |
| NLS Pharmaceutics AG | -11.79 Million USD | -5450.679% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 264944.913% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -2119.003% |
| Gritstone bio, Inc. | -126.86 Million USD | -416.099% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -907.523% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -16268.696% |
| Avid Bioservices, Inc. | -11.48 Million USD | -5602.805% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -29003.146% |
| MediWound Ltd. | -4.89 Million USD | -13281.136% |
| OmniAb, Inc. | -49.73 Million USD | -1216.561% |
| Alector, Inc. | -142.89 Million USD | -358.205% |
| Seres Therapeutics, Inc. | -85.43 Million USD | -666.368% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -1155.54% |
| Zai Lab Limited | -366.57 Million USD | -78.611% |
| Revance Therapeutics, Inc. | -290.63 Million USD | -125.277% |
| Aura Biosciences, Inc. | -83.69 Million USD | -682.282% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | -190.673% |
| Immunic, Inc. | -99.11 Million USD | -560.605% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | -397.258% |
| Veracyte, Inc. | -49.4 Million USD | -1225.141% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -9168.763% |
| FibroGen, Inc. | -261.4 Million USD | -150.469% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -5776.842% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -9251.64% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | -3398.123% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 145.172% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | -2475.482% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 1741.361% |
| TG Therapeutics, Inc. | 26.1 Million USD | 2608.579% |
| Galecto, Inc. | -37.51 Million USD | -1645.086% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -1611.065% |
| Fortrea Holdings Inc. | 167.3 Million USD | 491.356% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | -387.592% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | -2212.666% |
| XBiotech Inc. | -35.76 Million USD | -1730.618% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -907.523% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | -903.431% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | -526.814% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -2450.401% |
| Theravance Biopharma, Inc. | -40.86 Million USD | -1502.122% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | -26.776% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | -1068.739% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -1168012.969% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | -462.805% |
| Gain Therapeutics, Inc. | -22.16 Million USD | -2853.325% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | -178.536% |
| NexImmune, Inc. | -28.16 Million USD | -2224.448% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -11749.304% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -5452.272% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 114.068% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | -2478.525% |
| Scopus BioPharma Inc. | -11.71 Million USD | -5489.778% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | -420.27% |
| Ainos, Inc. | -8.77 Million USD | -7363.031% |
| Pluri Inc. | -20.22 Million USD | -3137.276% |
| Prothena Corporation plc | -190.1 Million USD | -244.404% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | -410.725% |
| Celularity Inc. | -183.94 Million USD | -255.941% |
| Rallybio Corporation | -72.37 Million USD | -804.673% |
| Cue Biopharma, Inc. | -46.05 Million USD | -1321.738% |
| MeiraGTx Holdings plc | -57.05 Million USD | -1047.618% |
| Omeros Corporation | -163.61 Million USD | -300.183% |
| Humacyte, Inc. | -96.45 Million USD | -578.781% |
| Immunocore Holdings plc | -59.64 Million USD | -997.653% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | -3279.821% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | -2587.211% |
| Blueprint Medicines Corporation | -474.61 Million USD | -37.952% |
| CalciMedica, Inc. | -34.18 Million USD | -1815.057% |
| Cabaletta Bio, Inc. | -73.23 Million USD | -794.037% |
| Scholar Rock Holding Corporation | -168.45 Million USD | -288.682% |
| Sana Biotechnology, Inc. | -252.39 Million USD | -159.416% |
| Pulmatrix, Inc. | -12.64 Million USD | -5077.44% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | -1886.104% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | -640.094% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | -29.315% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | -546.879% |
| Cytokinetics, Incorporated | -456.68 Million USD | -43.368% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -1861.882% |
| Nutriband Inc. | -5.12 Million USD | -12683.434% |
| Protara Therapeutics, Inc. | -43.27 Million USD | -1413.078% |
| Vor Biopharma Inc. | -114.37 Million USD | -472.469% |
| Roivant Sciences Ltd. | -996.51 Million USD | 34.297% |
| Evogene Ltd. | -23.2 Million USD | -2721.664% |
| ProKidney Corp. | -147.66 Million USD | -343.383% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -914.549% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -427417.646% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | -15.787% |
| CorMedix Inc. | -48.88 Million USD | -1239.29% |
| BioLineRx Ltd. | -57.06 Million USD | -1047.437% |
| Tango Therapeutics, Inc. | -111.75 Million USD | -485.854% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -324028.218% |
| Atai Life Sciences N.V. | -36.31 Million USD | -1703.142% |
| Renovaro Biosciences Inc. | -79.51 Million USD | -723.395% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | -705.208% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | -137.652% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -2029.925% |
| MediciNova, Inc. | -9.87 Million USD | -6526.933% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | -419.878% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -42687.778% |
| GeoVax Labs, Inc. | -26.66 Million USD | -2355.078% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -191.007% |
| Biomea Fusion, Inc. | -124.62 Million USD | -425.388% |
| PTC Therapeutics, Inc. | -330.34 Million USD | -98.202% |
| Mereo BioPharma Group plc | -26.05 Million USD | -2412.815% |
| Cullinan Oncology, Inc. | -190.33 Million USD | -243.986% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | -184.741% |
| Absci Corporation | -95.45 Million USD | -585.899% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -2080.646% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | -511.232% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | -180.431% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | -2764.752% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | -215.027% |
| Allakos Inc. | -189.91 Million USD | -244.754% |
| Imunon, Inc. | -19.87 Million USD | -3193.741% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | -503.491% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 704.427% |
| BioAtla, Inc. | -122.24 Million USD | -435.613% |
| NLS Pharmaceutics AG | -11.79 Million USD | -5450.679% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -4054.172% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | -118.033% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | -1479.702% |
| XOMA Corporation | -39.36 Million USD | -1563.378% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | -559.66% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -456.514% |
| aTyr Pharma, Inc. | -52.17 Million USD | -1154.818% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | -681.172% |
| Akero Therapeutics, Inc. | -148.63 Million USD | -340.513% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | -179.129% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -4695.569% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -8041.191% |
| Akari Therapeutics, Plc | -16.8 Million USD | -3796.792% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 347062.471% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 244.871% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -10148.512% |
| UroGen Pharma Ltd. | -63.83 Million USD | -925.738% |
| Sutro Biopharma, Inc. | -67.91 Million USD | -864.057% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -8914.704% |
| Orgenesis Inc. | -60.71 Million USD | -978.328% |
| Entera Bio Ltd. | -8.8 Million USD | -7336.836% |
| GH Research PLC | -41.15 Million USD | -1490.987% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | -2465.692% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | -696.2% |
| Xencor, Inc. | -125.87 Million USD | -420.154% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -45796.835% |
| Replimune Group, Inc. | -230.19 Million USD | -184.424% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | -3148.097% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -5883.723% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -10148.512% |
| Portage Biotech Inc. | -18.19 Million USD | -3497.665% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -42687.778% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | -526.041% |
| OncoCyte Corporation | -23.12 Million USD | -2731.549% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -5693.965% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -5614.831% |
| Purple Biotech Ltd. | -22.22 Million USD | -2845.957% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -10114.337% |
| scPharmaceuticals Inc. | -46.06 Million USD | -1321.461% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -3576.309% |
| HilleVax, Inc. | -132.46 Million USD | -394.269% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -6057.613% |
| Tharimmune, Inc. | -9.3 Million USD | -6938.245% |
| Genprex, Inc. | -31.06 Million USD | -2007.943% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | -249.146% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | -1988.215% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -85598.822% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 433977.83% |
| OKYO Pharma Limited | -15.74 Thousand USD | -4158063.379% |
| Savara Inc. | -59.13 Million USD | -1007.231% |
| Curis, Inc. | -45.13 Million USD | -1350.495% |
| Daré Bioscience, Inc. | -30.7 Million USD | -2032.595% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -4210.003% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -9038.018% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | -2349.087% |
| BeiGene, Ltd. | -1.12 Billion USD | 41.781% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -3916.508% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | -52.059% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | -624.75% |
| Erasca, Inc. | -121.31 Million USD | -439.724% |
| bluebird bio, Inc. | -167.16 Million USD | -291.682% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -14453.779% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 311.013% |
| DBV Technologies S.A. | -85.98 Million USD | -661.484% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -14453.779% |
| Moderna, Inc. | -3.28 Billion USD | 80.057% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -1436.621% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -11492.404% |
| Molecular Templates, Inc. | 1.43 Million USD | 45885.944% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | -993.93% |
| Travere Therapeutics, Inc. | -326.24 Million USD | -100.689% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | -377.601% |
| Spruce Biosciences, Inc. | -47.36 Million USD | -1282.297% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | -370.92% |
| Cogent Biosciences, Inc. | -205.86 Million USD | -218.051% |
| MacroGenics, Inc. | 2.01 Million USD | 32561.031% |
| RenovoRx, Inc. | -11.39 Million USD | -5648.367% |
| Adicet Bio, Inc. | -136.53 Million USD | -379.539% |
| Prime Medicine, Inc. | -193.75 Million USD | -237.914% |
| Aditxt, Inc. | -25.45 Million USD | -2471.844% |
| Adagene Inc. | -14.95 Million USD | -4279.295% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -8856.638% |
| Quantum-Si incorporated | -91.8 Million USD | -613.192% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 191.905% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 617.764% |
| SciSparc Ltd. | -5.28 Million USD | -12295.665% |
| Vericel Corporation | 2.86 Million USD | 22960.999% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -687593.261% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | -2918.423% |
| Generation Bio Co. | -133.3 Million USD | -391.177% |
| Astria Therapeutics, Inc. | -83.03 Million USD | -688.557% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | -661.121% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | -187.881% |
| Invivyd, Inc. | -196.61 Million USD | -233.006% |
| Relay Therapeutics, Inc. | -374.15 Million USD | -74.992% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -6959.334% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 2511.206% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -6265.96% |
| 2seventy bio, Inc. | -206.41 Million USD | -217.191% |
| ADMA Biologics, Inc. | 5.12 Million USD | 12887.871% |
| Clene Inc. | -43.24 Million USD | -1414.162% |
| Capricor Therapeutics, Inc. | -23 Million USD | -2745.581% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | -1250.618% |
| GeoVax Labs, Inc. | -26.66 Million USD | -2355.078% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | -118.563% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | -1682.604% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 2877.495% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 13434.114% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -1915.698% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | -313.335% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 4.321% |
| Evaxion Biotech A/S | -21.4 Million USD | -2959.099% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | -885.83% |
| Verve Therapeutics, Inc. | -217.66 Million USD | -200.796% |
| Trevena, Inc. | -35.28 Million USD | -1755.415% |
| Surrozen, Inc. | -41.13 Million USD | -1491.838% |
| Tyra Biosciences, Inc. | -79.59 Million USD | -722.619% |
| Cingulate Inc. | -22.95 Million USD | -2752.641% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -8675.486% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -1656.133% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -7859.026% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | -540.231% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | -865.307% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | -1021.666% |
| Clearmind Medicine Inc. | -8.71 Million USD | -7416.524% |
| Kronos Bio, Inc. | -121.83 Million USD | -437.42% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | -780.712% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -26718.024% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -549.369% |
| Statera Biopharma, Inc. | 38.93 Million USD | 1781.623% |
| ImmunityBio, Inc. | -436.18 Million USD | -50.107% |
| Korro Bio, Inc. | -80.9 Million USD | -709.279% |
| Kineta, Inc. | -15.71 Million USD | -4066.597% |
| BioVie Inc. | -31.95 Million USD | -1949.248% |
| Codexis, Inc. | -49.28 Million USD | -1228.529% |
| Celularity Inc. | -183.94 Million USD | -255.941% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | -195.58% |
| Celcuity Inc. | -58.3 Million USD | -1022.86% |
| Virax Biolabs Group Limited | -6.6 Million USD | -9806.563% |
| Cibus, Inc. | -314.58 Million USD | -108.128% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -1840.945% |
| IN8bio, Inc. | -28.5 Million USD | -2197.007% |
| Kodiak Sciences Inc. | -259.02 Million USD | -152.773% |
| Annexon, Inc. | -141.57 Million USD | -362.468% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | -481.479% |
| Assembly Biosciences, Inc. | -64.19 Million USD | -919.906% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | -2242.118% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | -184.657% |
| Eyenovia, Inc. | -24.1 Million USD | -2616.079% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 1561.993% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -201979.938% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | -787.132% |
| Arcellx, Inc. | -64.14 Million USD | -920.717% |
| Cardiff Oncology, Inc. | -45.01 Million USD | -1354.523% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | -430.256% |
| Regulus Therapeutics Inc. | -30.88 Million USD | -2020.131% |
| Moolec Science SA | -52.07 Million USD | -1157.287% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | -1168.727% |
| Geron Corporation | -174.78 Million USD | -274.603% |
| LAVA Therapeutics N.V. | -40.41 Million USD | -1519.959% |
| Royalty Pharma plc | 1.88 Billion USD | 134.692% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | -447.473% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -6921.892% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | -3056.775% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | -294.231% |
| Humacyte, Inc. | -96.45 Million USD | -578.781% |
| Structure Therapeutics Inc. | -102.45 Million USD | -539.025% |
| 89bio, Inc. | -134.46 Million USD | -386.929% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | -730.097% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 16258.416% |
| Genelux Corporation | -24.16 Million USD | -2609.452% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | -1837.098% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | -300.54% |
| Notable Labs, Ltd. | -14.4 Million USD | -4446.799% |
| Liquidia Corporation | -70.05 Million USD | -834.66% |
| Mustang Bio, Inc. | -48.06 Million USD | -1262.252% |
| Immunovant, Inc. | -269.97 Million USD | -142.516% |
| Quantum-Si incorporated | -91.8 Million USD | -613.192% |
| Arbutus Biopharma Corporation | -70.98 Million USD | -822.349% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | -3291.024% |
| Vera Therapeutics, Inc. | -102.01 Million USD | -541.825% |
| Acasti Pharma Inc. | -11.3 Million USD | -5693.638% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | -2842.218% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -4170.713% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | -211.021% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -15232.234% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -4023.042% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | -2175.295% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | -1668.131% |
| PepGen Inc. | -83.58 Million USD | -683.349% |
| Moleculin Biotech, Inc. | -29.5 Million USD | -2119.153% |
| United Therapeutics Corporation | 1.38 Billion USD | 147.212% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -2759.497% |
| Solid Biosciences Inc. | -93.43 Million USD | -600.75% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -13621.191% |
| Immuneering Corporation | -58.06 Million USD | -1027.678% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 20416033.895% |
| Silo Pharma, Inc. | -3.62 Million USD | -17955.719% |
| Belite Bio, Inc | -31.52 Million USD | -1976.625% |
| XOMA Corporation | -39.36 Million USD | -1563.378% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | -870.746% |
| Bionomics Limited | -9.83 Million USD | -6555.884% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | -679.59% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -1791.981% |
| uniQure N.V. | -253.1 Million USD | -158.688% |
| Cassava Sciences, Inc. | -95.68 Million USD | -584.251% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -8856.638% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | -405.574% |
| Forte Biosciences, Inc. | -32.47 Million USD | -1916.008% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -8032.926% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | -2220.206% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -201979.938% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -5776.842% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -4017.596% |
| Altimmune, Inc. | -87.93 Million USD | -644.572% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -611.062% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -1791.981% |
| Compugen Ltd. | -12.51 Million USD | -5131.216% |
| Peak Bio, Inc. | -1356.23 USD | -48276298.546% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | -1247.255% |
| Benitec Biopharma Inc. | -22.49 Million USD | -2811.245% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | -170.215% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | -2193.869% |
| Zura Bio Limited | -60.56 Million USD | -981.087% |
| PolyPid Ltd. | -20.26 Million USD | -3131.205% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -4093.55% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | -2193.869% |
| Instil Bio, Inc. | -146.12 Million USD | -348.077% |
| argenx SE | -216.02 Million USD | -203.088% |
| Immunome, Inc. | -28.27 Million USD | -2215.939% |
| Compass Therapeutics, Inc. | -48.47 Million USD | -1250.729% |
| Verona Pharma plc | -52.46 Million USD | -1147.892% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | -590.857% |
| Shattuck Labs, Inc. | -87.61 Million USD | -647.291% |
| CervoMed Inc. | -2.17 Million USD | -30046.27% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | -435.6% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -5058.268% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -1259.113% |
| Moolec Science SA | -52.07 Million USD | -1157.287% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -3719.951% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | -402.135% |
| AnaptysBio, Inc. | -143.16 Million USD | -357.335% |
| Design Therapeutics, Inc. | -66.32 Million USD | -887.168% |
| Leap Therapeutics, Inc. | -80.98 Million USD | -708.45% |
| NeurAxis, Inc. | -6.66 Million USD | -9724.285% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | -1634.408% |
| Lumos Pharma, Inc. | -36.57 Million USD | -1690.372% |
| Achilles Therapeutics plc | -70.44 Million USD | -829.472% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | -590.857% |
| 180 Life Sciences Corp. | -22.13 Million USD | -2858.065% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 11331.965% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -26718.024% |
| Nutriband Inc. | -5.12 Million USD | -12683.434% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | -496.584% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | -1081.157% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | -1195.23% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | -903.016% |
| MoonLake Immunotherapeutics | -54.1 Million USD | -1110.016% |
| Palisade Bio, Inc. | -12.28 Million USD | -5231.317% |
| Tourmaline Bio, Inc. | -45.37 Million USD | -1342.919% |
| Beam Therapeutics Inc. | -156.47 Million USD | -318.436% |
| Neurogene Inc. | -52.28 Million USD | -1152.226% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | -379.697% |
| AEON Biopharma, Inc. | -48.36 Million USD | -1253.857% |
| Sesen Bio, Inc. | -50.84 Million USD | -1187.842% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | -699.125% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -5201.52% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | -53.18% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | -522.393% |
| Athira Pharma, Inc. | -116.7 Million USD | -461.03% |
| Vaccinex, Inc. | -19.74 Million USD | -3215.47% |
| HCW Biologics Inc. | -23.57 Million USD | -2677.135% |
| XOMA Corporation | -39.36 Million USD | -1563.378% |
| Nektar Therapeutics | -243.1 Million USD | -169.321% |
| Arvinas, Inc. | -394.8 Million USD | -65.841% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 347062.471% |
| Merus N.V. | -149.2 Million USD | -338.813% |
| Omega Therapeutics, Inc. | -93.49 Million USD | -600.331% |
| Quince Therapeutics, Inc. | -31.26 Million USD | -1994.495% |
| Rezolute, Inc. | -68.42 Million USD | -856.899% |
| Clene Inc. | -43.24 Million USD | -1414.162% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -4145.435% |
| BeyondSpring Inc. | -21.54 Million USD | -2939.643% |
| Synlogic, Inc. | -55.16 Million USD | -1086.96% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -5318.679% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -6052.406% |
| Peak Bio, Inc. | -1356.23 USD | -48276298.546% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | -1916.753% |
| Krystal Biotech, Inc. | 17.9 Million USD | 3756.943% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | -452.882% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | -91.811% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -14113.582% |
| MannKind Corporation | 15.12 Million USD | 4427.708% |
| Ikena Oncology, Inc. | -74.39 Million USD | -780.061% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -5099.23% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 3321.031% |
| Gossamer Bio, Inc. | -172.15 Million USD | -280.326% |
| CohBar, Inc. | -12.06 Million USD | -5326.422% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | -2466.698% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -2080.646% |
| Legend Biotech Corporation | -477.87 Million USD | -37.011% |
| Mural Oncology plc | -192.72 Million USD | -239.736% |
| Biora Therapeutics, Inc. | -114.05 Million USD | -474.061% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -3955.299% |
| Disc Medicine, Inc. | -91.02 Million USD | -619.296% |
| Champions Oncology, Inc. | -5.05 Million USD | -12854.867% |
| REGENXBIO Inc. | -239.46 Million USD | -173.419% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -6008.673% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -1074.293% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | -1588.853% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | -480.412% |
| Vaxart, Inc. | -74.72 Million USD | -776.222% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | -1759.616% |
| Cellectis S.A. | -98.09 Million USD | -567.454% |
| Longeveron Inc. | -20.06 Million USD | -3163.903% |
| Repare Therapeutics Inc. | -114.27 Million USD | -472.96% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | -49.077% |
| Inozyme Pharma, Inc. | -74.81 Million USD | -775.179% |
| Revolution Medicines, Inc. | -430.58 Million USD | -52.059% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -10310.86% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | -2026.535% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -777.784% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 13453.845% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -5871.172% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 114.217% |
| Denali Therapeutics Inc. | -179.97 Million USD | -263.798% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -687593.261% |
| Veru Inc. | -89.97 Million USD | -627.685% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | -2335.966% |
| Cingulate Inc. | -22.95 Million USD | -2752.641% |
| Passage Bio, Inc. | -98.34 Million USD | -565.784% |
| Context Therapeutics Inc. | -25.06 Million USD | -2512.626% |
| Exicure, Inc. | -15.53 Million USD | -4113.521% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | -217.736% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | -1670.713% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -10880.771% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | -288.652% |
| Nuvalent, Inc. | -149.49 Million USD | -337.976% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -7950.979% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | -662.264% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | -2069.59% |
| OmniAb, Inc. | -49.73 Million USD | -1216.561% |
| Anew Medical, Inc. | -1.3 Million USD | -50232.016% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -5195.527% |
| Lipocine Inc. | -16.32 Million USD | -3911.226% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | -882.059% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | -781.174% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -1616.978% |
| G1 Therapeutics, Inc. | -39.01 Million USD | -1578.216% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | -2851.535% |
| Sage Therapeutics, Inc. | -545.07 Million USD | -20.12% |
| Ocugen, Inc. | -64.82 Million USD | -909.979% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | -607.291% |
| Q32 Bio Inc. | -86.5 Million USD | -656.906% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -3768.016% |
| Alumis Inc. Common Stock | -156.89 Million USD | -317.324% |
| Equillium, Inc. | -12.13 Million USD | -5294.126% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | -1019.748% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -8184.324% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -3371.395% |
| Galera Therapeutics, Inc. | -46.69 Million USD | -1302.251% |
| Evelo Biosciences, Inc. | -106.34 Million USD | -515.674% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -3560.502% |
| Dominari Holdings Inc. | -22.44 Million USD | -2817.732% |
| Edesa Biotech, Inc. | -8.19 Million USD | -7894.233% |
| vTv Therapeutics Inc. | -25.41 Million USD | -2476.495% |
| Bio-Techne Corporation | 326.66 Million USD | 300.433% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | -70.122% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 402.575% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | -399.389% |
| Candel Therapeutics, Inc. | -37.43 Million USD | -1649.189% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | -333.312% |
| Nkarta, Inc. | -120.48 Million USD | -443.438% |
| BioCardia, Inc. | -11.56 Million USD | -5563.832% |
| Iterum Therapeutics plc | -34.58 Million USD | -1793.404% |